Switch theme
Sign up to access all valuation multiples
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets.
2020
1K+
LTM Revenue $321M
LTM EBITDA $20.5M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GeneDx has a last 12-month revenue of $321M and a last 12-month EBITDA of $20.5M.
In the most recent fiscal year, GeneDx achieved revenue of $305M and an EBITDA of -$1.3M.
GeneDx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GeneDx valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $203M | $305M | XXX | XXX | XXX |
| Gross Profit | -$26.8M | $90.0M | XXX | XXX | XXX |
| Gross Margin | -13% | 29% | XXX | XXX | XXX |
| EBITDA | -$136M | -$1.3M | XXX | XXX | XXX |
| EBITDA Margin | -67% | 0% | XXX | XXX | XXX |
| Net Profit | -$549M | -$176M | XXX | XXX | XXX |
| Net Margin | -271% | -58% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, GeneDx's stock price is $101.
GeneDx has current market cap of $2.8B, and EV of $2.8B.
See GeneDx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $2.8B | XXX | XXX | XXX | XXX | $0.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, GeneDx has market cap of $2.8B and EV of $2.8B.
GeneDx's trades at 8.8x LTM EV/Revenue multiple, and 137.3x LTM EBITDA.
Analysts estimate GeneDx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for GeneDx and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 9.2x | XXX | XXX | XXX |
| EV/EBITDA | -2231.0x | XXX | XXX | XXX |
| P/E | -54.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -82.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGeneDx's NTM/LTM revenue growth is 17%
GeneDx's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, GeneDx's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate GeneDx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for GeneDx and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 51% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 0% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -99% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 17% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 71% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GeneDx acquired XXX companies to date.
Last acquisition by GeneDx was XXXXXXXX, XXXXX XXXXX XXXXXX . GeneDx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was GeneDx founded? | GeneDx was founded in 2020. |
| Where is GeneDx headquartered? | GeneDx is headquartered in United States of America. |
| How many employees does GeneDx have? | As of today, GeneDx has 1K+ employees. |
| Who is the CEO of GeneDx? | GeneDx's CEO is Ms. Katherine A. Stueland. |
| Is GeneDx publicy listed? | Yes, GeneDx is a public company listed on NAS. |
| What is the stock symbol of GeneDx? | GeneDx trades under WGS ticker. |
| When did GeneDx go public? | GeneDx went public in 2021. |
| Who are competitors of GeneDx? | Similar companies to GeneDx include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of GeneDx? | GeneDx's current market cap is $2.8B |
| What is the current revenue of GeneDx? | GeneDx's last 12-month revenue is $321M. |
| What is the current EBITDA of GeneDx? | GeneDx's last 12-month EBITDA is $20.5M. |
| What is the current EV/Revenue multiple of GeneDx? | Current revenue multiple of GeneDx is 8.8x. |
| What is the current EV/EBITDA multiple of GeneDx? | Current EBITDA multiple of GeneDx is 137.3x. |
| What is the current revenue growth of GeneDx? | GeneDx revenue growth between 2023 and 2024 was 51%. |
| Is GeneDx profitable? | Yes, GeneDx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
